Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

盘前交易 12-19 05:41:23 EST

120.25

-5.51

-4.38%

最高126.04	最低119.84	成交量94.28万
今开126.04	昨收125.76	日振幅4.93%
总市值114.86亿	流通市值109.60亿	总股本9,552万
成交额1.15亿	换手率1.03%	流通股本9,115万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":120.25,"timestamp":1734555600000,"preClose":125.76,"halted":0,"volume":942784,"delay":0,"floatShares":91146760,"shares":95519650,"eps":1.21982,"marketStatus":"盘前交易","marketStatusCode":1,"change":-5.51,"latestTime":"12-19 05:41:23 EST","open":126.04,"high":126.04,"low":119.84,"amount":114777536.35488,"amplitude":0.0493,"askPrice":148.71,"askSize":100,"bidPrice":118.21,"bidSize":140,"shortable":3,"etf":0,"ttmEps":1.21982,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734618600000},"adr":0,"listingDate":865396800000,"adjPreClose":120.25,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":120.25,"preClose":120.25,"latestTime":"19:57 EST","volume":173164,"amount":20822496.87,"timestamp":1734569830944},"volumeRatio":1.4998235751036684,"impliedVol":0.5435,"impliedVolPercentile":0.5458},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"2488167732","title":"Sarepta Therapeutics, Inc.盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488167732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488167732?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:51","pubTimestamp":1733151074,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时51分，Sarepta Therapeutics, Inc.股票出现异动，股价快速下挫5.02%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Senti Biosciences, Inc.、Cingulate Inc C/Wts 10/12/2026 、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Senti Biosciences, Inc.、Purple Biotech Ltd、Revelation Biosciences, Inc.较为活跃，换手率分别为1060.28%、781.47%、211.79%，振幅较大的相关个股有Senti Biosciences, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为136.57%、64.17%、43.48%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202225114abf00b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202225114abf00b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","BK4585","BK4139","SRPT","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LENZ","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2486215468","title":"BUZZ-两家券商上调 Arrowhead Pharma 在 Sarepta 交易后的市盈率","url":"https://stock-news.laohu8.com/highlight/detail?id=2486215468","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486215468?lang=zh_cn&edition=full","pubTime":"2024-11-27 21:27","pubTimestamp":1732714063,"startTime":"0","endTime":"0","summary":"BUZZ-两家券商上调 Arrowhead Pharma 在 Sarepta 交易后的市盈率11月27日 -  ** Arrowhead制药公司ARWR.O股价在收盘前上涨6.4%至22.39美元，而SareptaSRPT.O下跌1%至129.40美元。** 杰富瑞和Leerink Partners上调了对ARWR的评级 ，称 与SRPT的许可协议解决了Arrowhead的现金问题 ，使其能够专注于开发心脏代谢疗法。** 杰富瑞称，该交易将 ARWR 的现金流延长至 2028 年，使其 有足够的资源推出治疗罕见代谢紊乱的 plozasiran；将投资回报率提高了 2 美元，至 67 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nL3S3MY0Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","BK4588","IE0009355771.USD","IE00BFTCPJ56.SGD","SIVBQ","IE00BJT1NW94.SGD","ARWR","BK4139","BK4589","SRPT","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4585","BK4207","BK4211"],"gpt_icon":0},{"id":"2486001158","title":"Sarepta Therapeutics, Inc.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486001158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486001158?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:34","pubTimestamp":1732631660,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日22时34分，Sarepta Therapeutics, Inc.股票出现波动，股价大幅拉升5.08%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Poseida Therapeutics, Inc.、Fate Therapeutics, Inc.、Arrowhead Pharmaceuticals, Inc.涨幅较大，Oncternal Therapeutics, Inc.、Poseida Therapeutics, Inc.、Cognition Therapeutics, Inc.较为活跃，换手率分别为13.86%、10.42%、8.61%，振幅较大的相关个股有Exicure, Inc.、Caribou Biosciences, Inc.、Cabaletta Bio, Inc.，振幅分别为14.25%、13.61%、13.54%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126223421971a8a0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126223421971a8a0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SRPT","LENZ","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2486006769","title":"BUZZ-与 Sarepta 达成许可协议后，Arrowhead 制药公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2486006769","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486006769?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:24","pubTimestamp":1732631070,"startTime":"0","endTime":"0","summary":"11月26日 -  ** Arrowhead Pharmaceuticals ARWR.O宣布与Sarepta SRPT.O达成全球许可协议，该公司股价在盘前交易中大涨23.7%，报23.25美元。** ARWR 称与 Sarepta 就多个临床和临床前项目签署了许可与合作协议   ** Sarepta表示，Arrowhead将获得5亿美元的预付款和3.25亿美元的股权投资，同时Sarepta将获得7个项目的独家许可。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3S3MX17V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4139","IE0002141913.USD","ARWR","BK4588","SRPT","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"1126564074","title":"华尔街准备迎接特朗普时代的并购潮：哪些公司将成为新宠？","url":"https://stock-news.laohu8.com/highlight/detail?id=1126564074","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126564074?lang=zh_cn&edition=full","pubTime":"2024-11-18 11:31","pubTimestamp":1731900702,"startTime":"0","endTime":"0","summary":"随着特朗普即将就任美国总统，华尔街对并购活动可能复苏充满期待。然而，随着美国大选结束，FTC 的领导层可能发生改变，华尔街正为一个新的并购时代做好准备。潜在趋势特朗普的胜选恰逢并购业务已开始复苏的节点。被法官阻止后上周两家公司宣布终止合并，但未来仍可能参与其他交易。潜在问题虽然特朗普的第二个任期预计将比拜登总统更有利于商业，但新政府的反垄断政策仍存在不确定性。","market":"us","thumbnail":"https://static.tigerbbs.com/1132cf4a91e17479cbdbd4a7fdf04a3b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1132cf4a91e17479cbdbd4a7fdf04a3b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"华尔街准备迎接特朗普时代的并购潮：哪些公司将成为新宠？","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","EA","S","HIMS","ZM","SAVE","FOUR","ELF","COF","DUOL","FRPT","TPR","BROS","DFS"],"gpt_icon":1},{"id":"2483309832","title":"Sarepta Therapeutics, Inc.2024财年第三财季实现净利润33.61百万美元，同比增加182.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483309832?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686428,"startTime":"0","endTime":"0","summary":"11月16日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为33.61百万美元，同比增加182.10%；其中营业收入为4.67亿美元，同比增加40.66%，每股基本收益为0.35美元。从资产负债表来看，Sarepta Therapeutics, Inc.总负债23.79亿美元，其中短期债务91.60百万美元，资产负债比为1.52，流动比率为3.85。机构评级：截至2024年11月16日，当前有20家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为192.00美元，其中最低目标价为150.00美元，最高目标价为219.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000208a23b88d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000208a23b88d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SRPT"],"gpt_icon":0},{"id":"2483335814","title":"健康查房：疫苗显示抗侵袭性乳腺癌的早期前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2483335814","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483335814?lang=zh_cn&edition=full","pubTime":"2024-11-15 03:11","pubTimestamp":1731611481,"startTime":"0","endTime":"0","summary":"寻找有效癌症疫苗的努力成果有限，但一种针对侵袭性最强的乳腺癌的实验性疫苗正在进行测试，显示出了早期的希望。18名新确诊的三阴性乳腺癌患者在接受了标准化疗和切除肿瘤的手术后，接种了三剂个性化疫苗，但这些肿瘤尚未扩散到其他器官。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4S3ML1S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","SRPT","BK4585","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4139","IE0009355771.USD"],"gpt_icon":0},{"id":"2481305591","title":"BUZZ-Sarepta 因决定停产杜兴氏症新药而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2481305591","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481305591?lang=zh_cn&edition=full","pubTime":"2024-11-08 03:07","pubTimestamp":1731006453,"startTime":"0","endTime":"0","summary":"11月7日 -  ** 疗法生产商Sarepta Therapeutics SRPT.O股价下跌6.7%至119.42美元  ** 公司表示将停止开发用于治疗杜氏肌营养不良症患者的新实验药物SRP-5051   ** 杜兴氏肌肉萎缩症是一种导致骨骼肌和心肌无力的疾病，随着时间的推移会迅速恶化 ** 在少数患者中，尽管停止了治疗，公司仍发现了持续性低镁血症--血液中的镁含量低于正常水平的病症 ** 该公司在电话会议上说，它将停止开发用于治疗杜兴氏肌肉萎缩症的整个多肽共轭 PMO 药物专营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME2LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","IE0009355771.USD","SRPT","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"1143231034","title":"异动解读 | Sarepta Therapeutics业绩超预期 主力产品销售增长推动股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1143231034","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143231034?lang=zh_cn&edition=full","pubTime":"2024-11-08 00:58","pubTimestamp":1730998728,"startTime":"0","endTime":"0","summary":"美国生物制药公司Sarepta Therapeutics11月7日盘前大涨近4%,股价上涨至132.97美元。公司此前公布的第三季度财报数据显示,营收4.672亿美元,高于华尔街分析师此前的4.093亿美元预期,主要得益于旗舰产品Elevidys销售表现亮眼。Elevidys是SRPT公司主要针对治疗罕见疾病杜氏肌营养不良症推出的基因疗法药物,第三季度产品净收入达1.81亿美元。公司称,该药品能有效改善该疾病 young患者的生存质量。杜氏肌营养不良症会导致骨骼及心肌变弱无力,患者病情随时间推移会迅速恶化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Sarepta Therapeutics业绩超预期 主力产品销售增长推动股价大涨","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"2481900251","title":"BUZZ-Sarepta 第三季度收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2481900251","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481900251?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:54","pubTimestamp":1730987658,"startTime":"0","endTime":"0","summary":"11月7日 -  ** 疗法生产商 Sarepta Therapeutics SRPT.O股价盘前上涨 3.91% 至 132.97 美元 ** 公司报告  第三季度营收 4.672 亿美元，超过分析师预期的 4.093 亿美元 - LSEG 数据 ** Elevidys  第三季度产品净收入为 1.81 亿美元，是其治疗杜氏肌营养不良症的基因疗法。** 杜氏肌营养不良症是一种导致骨骼肌和心肌无力的疾病，会随着时间的推移迅速恶化 ** 公司表示将停止开发用于治疗杜氏肌营养不良症患者的 SRP-5051 疗法。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME1NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4139","IE0009355771.USD","BK4585","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2476486769","title":"消费者团体要求美国联邦贸易委员会阻止诺和诺德控股公司与卡塔伦特公司的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2476486769","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476486769?lang=zh_cn&edition=full","pubTime":"2024-10-18 02:00","pubTimestamp":1729188006,"startTime":"0","endTime":"0","summary":"        *      消费者团体和工会向美国联邦贸易委员会表达竞争担忧        *      交易可能会限制开发 GLP-1 药物的竞争对手的选择        *      对基因疗法生产的影响也引起了关注   Jody Godoy/Maggie Fick    路透纽约10月17日 - 五个美国消费者团体和两个大型工会周四敦促美国联邦贸易委员会阻止诺和诺德公司  的控股股东收购合同药品制造商康泰伦特  ，称该交易威胁到减肥药和尖端基因疗法领域的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE0002270589.USD","SG9999001176.USD","BK4581","LU0289739699.SGD","CTLT","LU0321505868.SGD","LU1066053197.SGD","LU1894683264.USD","SG9999001176.SGD","BK4532","IE0002141913.USD","LU0058720904.USD","BK4588","LU0306806265.USD","LU1894683348.USD","BK4533","LU0225771236.USD","LU0170899867.USD","LU1093756168.USD","LU0225284248.USD","GPCR","SG9999013999.USD","LU0456855351.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","LU2242646821.SGD","LU2112291526.USD","LU0109394709.USD","BK4534","IE00BBT3K403.USD","BK4139","LU0321505439.SGD","LU1023059063.AUD","AMGN","SG9999003800.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","NVO","SGXZ57979304.SGD","LU1057294990.SGD","SRPT","LLY","BK4592","VKTX","LU0320765992.SGD","SG9999011175.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2474274746","title":"Sarepta Therapeutics, Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474274746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474274746?lang=zh_cn&edition=full","pubTime":"2024-10-10 22:48","pubTimestamp":1728571683,"startTime":"0","endTime":"0","summary":"北京时间2024年10月10日22时48分，Sarepta Therapeutics, Inc.股票出现波动，股价急速上涨5.00%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Tc Biopharm  Plc C/Wts 10/02/2028 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 涨幅较大，Aditxt, Inc.、Tempest Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为278.51%、149.24%、107.68%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为66.67%、49.35%、40.50%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101022480398e3bbf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101022480398e3bbf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE0009355771.USD","IE00BJT1NW94.SGD","SRPT","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD","BK4139","LENZ","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2470298291","title":"BUZZ-DMD 药物数据给人留下深刻印象，生命之波继续飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2470298291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470298291?lang=zh_cn&edition=full","pubTime":"2024-09-26 00:53","pubTimestamp":1727283197,"startTime":"0","endTime":"0","summary":"* * 该公司称， 根据中期研究的中期数据，其治疗杜氏肌营养不良症部分患者的药物 安全且耐受性良好， 。** 该公司称，WVE-N531药物的平均绝对肌营养不良蛋白产量为正常水平的5.5     ** 雷蒙德-詹姆斯将 WVE 评为 \"跑赢大盘\"，并将预测价格上调 2 美元至 13 美元。** Leerink Partners 在周二下午的报告中重申 \"跑赢大盘\"，并将预测价格上调 4 美元至 20 美元。** 数据更新进一步验证并降低了平台风险，Leerink 分析师说。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211327993.USD","IE00BFXG1179.USD","BK4566","BK4534","IE00BLSP4239.USD","IE00BLSP4452.SGD","IE00BJTD4N35.SGD","LU","IE00BJT1NW94.SGD","LU1261432733.SGD","IE00BHPRN162.USD","LU0106831901.USD","LU1244550577.SGD","LU0234572021.USD","LU0211328371.USD","BK4007","IE00B3S45H60.SGD","BK4516","LU0496365809.HKD","LU0149725797.USD","IE00BWXC8680.SGD","LU0320765646.SGD","WVE","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","IE0034235188.USD","LU0211326839.USD","IE00BJTD4V19.USD","LU0267386448.USD","LU0208291251.USD","LU0211331839.USD","BK4550","IE0002141913.USD","IE00BZ1G4Q59.USD","LU0310799852.SGD","LU0211326755.USD","LU1668664300.SGD","LU1363072403.SGD","LU0215105999.USD","LU1244550221.USD","LU0203347892.USD","SRPT","IE00B775SV38.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU1496350171.SGD","IE00BJJMRZ35.SGD","LU0203345920.USD","BK4533","LU0256863811.USD"],"gpt_icon":0},{"id":"2460242249","title":"Sarepta Therapeutics, Inc.2024财年第二财季实现净利润6.46百万美元，同比增加126.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460242249","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460242249?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824028,"startTime":"0","endTime":"0","summary":"8月17日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为6.46百万美元，同比增加126.98%；其中营业收入为3.63亿美元，同比增加39.08%，每股基本收益为0.07美元。从资产负债表来看，Sarepta Therapeutics, Inc.总负债23.47亿美元，其中短期债务91.51百万美元，资产负债比为1.46，流动比率为3.91。机构评级：截至2024年8月17日，当前有18家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为195.83美元，其中最低目标价为148.00美元，最高目标价为220.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000419959f2b57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000419959f2b57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SRPT","LENZ"],"gpt_icon":0},{"id":"2457314738","title":"Sarepta Therapeutics, Inc.盘中异动 快速下挫5.06%报132.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457314738","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457314738?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:57","pubTimestamp":1723125421,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时57分，Sarepta Therapeutics, Inc.股票出现异动，股价大幅跳水5.06%。截至发稿，该股报132.97美元/股，成交量63.2173万股，换手率0.66%，振幅2.91%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.13%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808215702aefdf111&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808215702aefdf111&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","BK4585","BK4139","SRPT","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LENZ","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2457732550","title":"BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX","url":"https://stock-news.laohu8.com/highlight/detail?id=2457732550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457732550?lang=zh_cn&edition=full","pubTime":"2024-08-07 00:30","pubTimestamp":1722961818,"startTime":"0","endTime":"0","summary":"美东时间12:14，道琼斯工业平均指数  上涨1.22%，报39,175.66点。标普500指数  上涨1.74%，报5276.66点；纳斯达克综合指数  上涨1.81%，报16492.856点。** CVS Health Corp   ：下跌 0.5%BUZZ - 巴克莱认为，成本上升趋势对 CVS 第二季度和全年利润构成风险   ** Jacobs Solutions Inc   ：上涨 1.2%BUZZ - 在第三季度收入超预期后上涨   ** IDEXX Laboratories Inc   ：上涨 4.3%BUZZ - 在预期下调并不像人们担心的那样糟糕之后，在缓解性反弹中上涨   标准普尔 500 指数的 11 个主要行业：通信服务","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TALK","HIMS","ELEV","IDXX","ZI","BUZZ","DXD",".IXIC","ZTS","PSQ","J","BMRN","BVS","HSIC",".SPX","MCK","MNQmain","SPWR","UDOW",".DJI","QID","SDOW","MKTX","SRPT","BR","KVUE","DDM","MPC","TDG","NQmain","GEHC","EXPD","FIS","SQQQ","BAX","TAP","TQQQ","CVS","OGN","CSX","VNO","DJX","LUMN","CAT"],"gpt_icon":1},{"id":"2457704198","title":"BUZZ-莱林克认为礼来和 Sarepta 是动荡市场中的防御性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2457704198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457704198?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:36","pubTimestamp":1722947798,"startTime":"0","endTime":"0","summary":"    8月6日 - ** 经纪公司Leerink Partners称，礼来  和Sarepta Therapeutics  等股票有望在经济衰退的 \"动荡时期 \"跑赢大盘。** 默克  、Vaxcyte  和布鲁克  属于 \"现在值得重新审视 \"的股票，因为目前的抛售是买入这些股票的近期机会，这些股票最近因新闻流或股价表现困难而面临压力--Leerink** BMO Capital Markets称，SRPT、CRISPR Therapeutics   、Biomarin   和Legend Biotech   等公司因其强劲的产品收入而被 \"低估\"，这些公司可在大幅下跌时提供保护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","LU1814569148.SGD","MCK","LU0211331839.USD","LU0868494617.USD","LU2125909247.SGD","BK4548","LU0251131958.USD","LU1066051225.USD","BK4559","LU0109391861.USD","LLY","LU1093756168.USD","LU1023059063.AUD","LU1280957306.USD","LU1988902786.USD","BK4534","SGXZ23171101.USD","COR","BK4121","LEGN","LU1037948897.HKD","BK4535","IE00B19Z3B42.SGD","TMO","IE00BJJMRZ35.SGD","LU0208291251.USD","LU1066051811.HKD","IE00BLSP4239.USD","LU0251142724.SGD","LU0256863811.USD","BK4533","IE00BJT1NW94.SGD","LU0471298694.HKD","LU1989771016.USD","IE00BJLML261.HKD","BK4007","IE0002270589.USD","BUZZ","SRPT","LU0058720904.USD","LU1066051498.USD","LU2112291526.USD","LU0965509283.SGD","LU1551013342.USD","IE00BBT3K403.USD","BMRN","IE00BKPKM429.USD","PCVX"],"gpt_icon":1},{"id":"2457058236","title":"Sarepta Therapeutics Inc   预计每股收益1美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457058236","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457058236?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:08","pubTimestamp":1722910085,"startTime":"0","endTime":"0","summary":"   * Sarepta Therapeutics Inc    将于8月7日公布截至0001年1月1日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司预计将实现49.8%的营收增长，从去年同期的2.6124亿美元增至3.914亿美元。* LSEG 分析师对 Sarepta Therapeutics Inc 的平均预期为每股收益 1 美分。* 华尔街对 Sarepta Therapeutics Inc 的 12 个月目标价中位数为 200.00 美元，高于其上次收盘价 140.65 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SRPT"],"gpt_icon":0},{"id":"2455198651","title":"Sarepta Therapeutics Inc   预计每股收益1美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455198651","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455198651?lang=zh_cn&edition=full","pubTime":"2024-07-29 20:05","pubTimestamp":1722254708,"startTime":"0","endTime":"0","summary":"   * Sarepta Therapeutics Inc    预计将于7月31日公布截至2024年6月30日的季度业绩(预计)，季度收入将有所增长。* LSEG 分析师对 Sarepta Therapeutics Inc 的平均预期为每股收益 1 美分。* 华尔街对 Sarepta Therapeutics Inc 的 12 个月目标价中位数为 200.00 美元，高于其上一交易日 144.24 美元的收盘价。7月29日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","LENZ"],"gpt_icon":0},{"id":"2455311916","title":"Sarepta Therapeutics公司：RBC将其评级从“板块表现”上调至“跑赢大盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2455311916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455311916?lang=zh_cn&edition=full","pubTime":"2024-07-29 17:26","pubTimestamp":1722245197,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SRPT","LENZ","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":-0.041},{"period":"1month","weight":0.1488},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.2518},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.247}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055118},{"month":3,"riseRate":0.5,"avgChangeRate":0.024789},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0.75,"avgChangeRate":0.176958},{"month":6,"riseRate":0.75,"avgChangeRate":0.09879},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001448},{"month":8,"riseRate":0.692308,"avgChangeRate":0.083301},{"month":9,"riseRate":0.538462,"avgChangeRate":0.134393},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.09314},{"month":11,"riseRate":0.769231,"avgChangeRate":0.088799},{"month":12,"riseRate":0.538462,"avgChangeRate":0.010333}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况